Interferon beta as antibacterial agents
The present invention describes method of treating bacterial infections, including MRSA. In various embodiments, the methods can use interferon beta, which is found to have antimicrobial activity. In certain embodiments, the interferon beta can be human interferon beta. In other embodiments, the interferon beta can be mouse interferon beta. In further embodiments, the interferon beta can be human interferon beta containing amino acid substitutions to make the human interferon beta more cationic in neutral pH.
1. A method for directly killing gram-positive bacteria in a subject in need thereof, comprising: providing a composition comprising interferon-β (IFNβ); and administering the composition to the subject in a dose sufficient to directly kill the gram-positive bacteria, wherein gram-positive bacteria is S. aureus or methicillin resistant S. aureus (MRSA) or Staphylococcus epidermidis.
2. The method of claim 1 , wherein administering the composition comprises parenteral administration or transdermal administration.
3. The method of claim 1 , wherein the gram-positive bacteria is S. aureus.
4. The method of claim 1 , wherein the gram-positive bacteria is methicillin resistant S. aureus (MRSA).
5. The method of claim 1 , wherein the gram-positive bacteria is Staphylococcus epidermidis.
6. The method of claim 1 , wherein the IFNβ is mouse IFNβ.
7. The method of claim 1 , wherein the IFNβ is human IFNβ.
8. The method of claim 1 , wherein the IFβ1 is IFNβ1.
9. The method of claim 8 , wherein the IFNβ1 is mouse IFNβ1.
10. The method of claim 8 , wherein the IFNβ1 is human IFNβ1.
11. The method of claim 8 , wherein the IFNβ1 is IFNβ1 a.
12. The method of claim 11 , wherein the IFNβ1a is human IFNβ1a.
13. The method of claim 8 , wherein the IFNβ1 is IFNβ1b.
14. The method of claim 13 , wherein the IFNβ1b is human IFNβ1b.